Abstract
Corticotropin-releasing hormone (CRH) receptor type 1 (CRF1) is a member of the receptor family mediating the effects of CRH, a critical neuromediator of stress-related endocrine, autonomic, and behavioral responses. The detailed organization and fine localization of CRF1-like immunoreactivity (CRF1-LI) containing neurons in the rodent have not been described, and is important to better define the functions of this receptor. Here we characterize in detail the neuroanatomical distribution of CRF1-immunoreactive (CRF1-ir) neurons in the mouse brain, using an antiserum directed against the C-terminus of the receptor. We show that CRF1-LI is abundantly yet selectively expressed, and its localization generally overlaps the target regions of CRH-expressing projections and the established distribution of CRF1 mRNA, with several intriguing exceptions. The most intensely CRF1-LI-labeled neurons are found in discrete neuronal systems, i.e., hypothalamic nuclei (paraventricular, supraoptic, and arcuate), major cholinergic and monoaminergic cell groups, and specific sensory relay and association thalamic nuclei. Pyramidal neurons in neocortex and magnocellular cells in basal amygdaloid nucleus are also intensely CRF1-ir. Finally, intense CRF1-LI is evident in brainstem auditory associated nuclei and several cranial nerves nuclei, as well as in cerebellar Purkinje cells. In addition to their regional specificity, CRF1-LI-labeled neurons are characterized by discrete patterns of the intracellular distribution of the immunoreaction product. While generally membrane associated, CRF1-LI may be classified as granular, punctate, or homogenous deposits, consistent with differential membrane localization. The selective distribution and morphological diversity of CRF1-ir neurons suggest that CRF1 may mediate distinct functions in different regions of the mouse brain.
Indexing terms: CRH, CRF, CRF-R1, rodent, immunocytochemistry, central nervous system
Corticotropin-releasing hormone (CRH), a 41-amino acid neuropeptide, is the primary hypothalamic factor involved in controlling the synthesis and release of adrenocorticotropic hormone (ACTH) from the anterior pituitary (Vale et al., 1981). A large body of evidence indicates that CRH acts as a physiological mediator of stress-related functions (Aldenhoff et al., 1983; Ehlers et al., 1983; Siggins et al., 1985; Swanson et al., 1986; Conti and Foote, 1995; Sawchenko et al., 1996; Baram and Hatalski, 1998). CRH has also been demonstrated to be widely distributed throughout the brain (Swanson et al., 1983; Sawchenko and Swanson, 1985; Imaki et al., 1991; Sawchenko et al., 1993). In several regions, the peptide has been shown to have many of the physiological characteristics of a neurotransmitter (Young et al., 1986; Powers et al., 1987; Valentino and Wehby, 1988; Sawchenko et al., 1993).
The actions of CRH are mediated via interaction with distinct CRH receptors (Grigoriadis et al., 1996). Two general members of the CRH receptor family are currently known and consist of membrane-spanning G-protein-coupled molecules. The first, CRF1 (or CRF-R1), has been cloned and functionally characterized in a number of species (Chang et al.,1993; Chen et al., 1993; Perrin et al., 1993; Palchaudhuri et al., 1998). This receptor binds CRH with high affinity and is positively linked to adenylate cyclase. Rat CRF1 is found in the pituitary and the central nervous system (CNS) and is the candidate mediator for many of the neuroendocrine and neuromodulatory effects of CRH (De Souza et al., 1985; Potter et al., 1994; Chalmers et al., 1995; Baram et al., 1997; Radulovic et al., 1998). The amino acid sequence of mouse CRF1 is highly similar to that of rat CRF1 (Vita et al., 1993). However, recently, Radulovic et al. (1998) showed that CRF1 is differently glycosylated in rat and mouse, as indicated by a higher molecular weight of mouse CRF1 protein. These authors, using Western blotting, also suggested that the mouse CRF1 may not share the regional brain distribution of the rat receptor. The second receptor, CRF2, is found in at least three subtypes in human and rat (CRF2α, CRF2β, and CRF2γ), one of which, CRF2α is found primarily in the CNS (Lovenberg et al., 1995; Kostich et al., 1998).
The distributions of messenger RNAs (mRNAs) of the two CRH receptors in rat brain have been demonstrated using in situ hybridization. Thus, Potter et al. (1994) and Chalmers et al. (1995) described, respectively, the anatomical distribution of CRF1 mRNA and CRF2 mRNA in adult rat brain, demonstrating distinct patterns for each of these receptors. Also, significant differences in CRH receptor mRNA distribution have been described in different species (Sanchez et al., 1999). Importantly, the detailed organization and the fine localization of CRF1 in rodent brain have not been delineated. In addition, mRNA analysis does not provide information about the intracellular localization of CRF1 to somata versus processes, or about clustering and synaptic relationships of receptor molecules. Therefore, the goal of the present study was to utilize immunocytochemical methods to provide a detailed, single-cell-resolution description of the distribution of CRF1 in the mouse brain.
MATERIALS AND METHODS
Animals
Adult male C57 black mice (2 months old) were used in this study. Because the overall goals of this series of studies included understanding the possible regulation of CRF1 by its ligand, CRH, care was taken to utilize mice of similar genetic make-up in all stages of this effort. Therefore, mice used here were progeny of breeding pairs heterozygous for a null CRH allele (a generous gift from Dr. J Majzoub). Specifically, transgenic mice in whom an allele of the CRH gene has been replaced with a neomyocin resistance gene were crossed back to the C57 background strain for a minimum of 14 generations. Progeny of heterozygous breeding pairs were genotyped by polymerase chain reaction analysis (Muglia et al., 1995), and those found to possess both alleles of the CRH gene (wild type) were used in this study.
To account for potential variation in CRF1 distribution or abundance deriving from the specific strain or genetic make-up of these mice, brains from two additional mice from a separate strain (129/Ola or CD1 strain) were also studied, with essentially indistinguishable results (not shown). Mice were born and maintained in a federally approved animal facility, and litter size was culled to six. Mice were kept on a 12-hour light/dark cycle and given free access to food and water. All experiments were carried out according to NIH guidelines for the care of experimental animals, with approval by the institutional animal care committee.
Antiserum generation
A polyclonal anti-CRF1 antiserum was generated in goat, against a 20-amino acid peptide sequence (Santa Cruz Biotechnology, Santa Cruz, CA). The synthetic peptide antigen, comprising the C-terminus of CRF1 (SIPTSPTRVSFHSIKQSTAL), corresponds to amino acids 425–444 of human CRF1 and is identical with amino acids 396–415 of mouse and rat CRF1. This sequence differs by three amino acids from the corresponding portion (412–431) of mouse CRF2. A search of GenBank and SwissProt data bases revealed no known sequences (aside from CRH receptors of other species) with significant homology to this portion of the CRF1 receptor. To characterize the antigen interacting with the antiserum further, Western blotting was also carried out. To determine whether cross-reactivity with the CRF2 receptor occurred at the dilution used in this study (as suggested by the manufacturer), sections of mouse heart, known to express only the CRF2 receptor, were subjected to immunocytochemistry in parallel with brain sections.
Western blotting
Brains were rapidly dissected from adult mice of two strains that were killed by decapitation. The hypothalamus and cerebellum were then separated carefully and homogenized in 50 mM Tris-HCl (pH 7.4, 4°C) containing 150 mM NaCl, 0.25% sodium dodecyl sulfate (SDS), 0.25% sodium deoxycholate, 1 mM EDTA, 2 µg/ml aprotinin, 2 µg/ml leupeptin, and 2 µg/ml pepstatin. The crude extracts were centrifuged at 14,000 rpm for 20 minutes at 4°C. The supernatant was collected and centrifuged for 10 minutes. The clear supernatant fluid (containing soluble proteins and membrane fraction) was then collected for the following analysis. Protein concentration was determined using BCA Protein Assay (Pierce, Rockford, IL), and 50-µg protein aliquots were size-fractionated on 4–12% Tris-glycine gel (Novex, Carlsbad, CA) at 120 V for 2.5 hours.
After electrophoresis, proteins were transferred to Hybond-ECL membrane (Amersham, Arlington Heights, IL). Nonfat milk (6%) in Tris-buffered saline (25 mM Tris, 0.15 M NaCl, pH 7.2) containing 0.05% Tween-20 (TBS-T) was used for blocking and for dilution of primary and secondary antibodies. The membrane was blocked overnight at 4°C and then incubated for 2 hours at room temperature with the anti-CRF1 antiserum (1:500). After several washes with TBS-T, the membrane was incubated in horseradish peroxidase-conjugated anti-goat IgG (1:10,000, Jackson ImmunoResearch, West Grove, PA) for 1.5 hours at room temperature. Following rinsing with TBS-T, bound antibody was detected using the ECL detection system (Amersham). For control, the primary antiserum was preadsorbed overnight at 4°C with purified CRF1 blocking peptide (100 µg/ml; Santa Cruz Biotechnology).
Immunocytochemistry
Care was taken to harvest tissue under relatively stress-free conditions (Yan et al., 1998a,b). Briefly, mice (n = 4) were undisturbed for at least 24 hours prior to experiments and then deeply anesthetized with sodium pentobarbital (100 mg/kg intraperitoneally) within 45 seconds of initial handling. Mice were then removed to the laboratory and perfused via the ascending aorta with 0.9% saline solution followed by freshly prepared 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB, pH 7.4, 4°C). Brains were dissected from the skull, postfixed for 4 hours, and immersed in 15%, followed by 25% sucrose for cryoprotection. Brains were blocked in the coronal or sagittal planes and sectioned at 20-µm thickness using a cryostat. In each plane, one in eight matched sections (one in four for the hypothalamic region) were subjected to immunocytochemistry, and an adjacent series of sections was stained with cresyl violet.
For CRF1-LI immunocytochemistry, free-floating sections were collected into tissue-culture wells in 0.1 M PB and subjected to standard avidin-biotin complex (ABC) methods (Chen et al., 1998a; Yan et al., 1998a,b). Briefly, after several washes with 0.01 M phosphate-buffered saline (PBS) containing 0.3% Triton X-100 (pH 7.4, PBS-T), sections were treated for 30 minutes in 0.3% H2O2 in PBS, followed by blockade of nonspecific sites with 2% normal rabbit serum in PBS for 30 minutes. After a 10-minute rinse in PBS, sections were incubated for 48 hours at 4°C with anti-CRF1 (1:5,000) in PBS containing 1% bovine serum albumin and 2% normal rabbit serum and washed 3 times in PBS-T, 5 minutes each. Subsequently, sections were incubated in biotinylated rabbit-anti-goat IgG (1: 200, Vector, Burlingame, CA) in PBS for 1 hour at room temperature. After washing in PBS-T (3 × 5 minutes), sections were incubated in ABC solution (1:100; Vector) for 2 hours at room temperature. Sections were then rinsed again in PBS-T (3 × 5 minutes). The reaction product was visualized by incubating sections for 8–10 minutes in 0.04% 3,3′-diaminobenzidine (DAB) containing 0.01% H2O2 with or without 0.5% nickel chloride.
Several approaches were used to address the specificity of the immunostaining obtained with anti-CRF1. In addition to the Western blotting described above, the specificity of the primary antiserum was also tested by substituting normal goat IgG (1:1,000–5,000; Santa Cruz Biotechnology) for the primary antiserum and by preadsorbing the antiserum overnight with purified CRF1 blocking peptide (100 µg/ml). The specificity of the second antibody was tested by omitting the primary antiserum during the first incubation. As indicated above, cross-reactivity with CRF2 was tested by using the antiserum for staining mouse heart tissue, known to express CRF2 only.
Regional and laminar distribution patterns of CRF1-LI were determined by comparison of immunocytochemical sections with adjacent cresyl-violet stained sections and by evaluation of methyl green-counterstained sections. Published nomenclature was used to identify cytoarchitectonic areas in the cortex (Dolorfo and Amaral, 1998), amygdala (Pitkänen et al., 1997), hypothalamic paraventricular nucleus (Swanson and Kuypers, 1980; Swanson et al., 1983), and other regions (Sidman et al., 1971; Paxinos and Watson, 1982).
Density and intensity of CRF1-LI-labeled neurons
The relative density of CRF1-ir neurons was assessed with a square lattice system (Chen et al., 1998b) over the entire area examined, using light microscopy at ×400 magnification. Density was expressed as the percentage of positive cells related to total cell number in the region of interest or in a 0.01-mm2 real area, based on the average value from three fields per section. Generally, three to five sections were counted in every mouse for evaluating CRF1-ir neuronal density in each brain structure or nucleus, and the percentage of CRF1-ir neurons was calculated by dividing the total number of CRF1-ir neurons by the sum of Nissl-stained cells. The intensity of CRF1-LI labeling was scored as weak (+), moderate (++), intense (+++), or strongly intense (++++).
RESULTS
The specificity of the anti-CRF1 antiserum was assessed by immunoblotting mouse hypothalamus and cerebellum homogenates (Fig. 1). As shown in lanes 1 and 2, the antiserum recognized an approximately 80-kDa protein, in good agreement with the molecular weight of mouse brain CRF1 protein (Radulovic et al., 1998). Preadsorption of the primary antiserum with a blocking peptide consisting of the immunogenic epitope (100 µg/ml) completely abolished the CRF1 band (Fig. 1, lanes 3 and 4). The specificity of CRF1 immunoreactivity was also indicated by the absence of labeled neurons or fibers in brain sections that were stained using antiserum pretreated with the antigenic peptide (Fig. 2D). In addition, no staining was observed on the sections when normal goat IgG was substituted for the CRF1-directed serum or in the absence of the primary antiserum (not shown). Finally, cross-reactivity with the CRF2 receptor was excluded by the absence of any signal in mouse heart specimens run in parallel to immunopositive brain sections (not shown).
CRF1-LI neurons were widely but selectively distributed throughout the mouse brain. In addition, the intensity of CRF1 reaction product in positive neurons differed in a neuron- and region-specific manner. In general (but not always; see Fig. 2C), CRF1-LI in most involved brain regions showed a pattern typical of membrane localization and was further characterized as either granular (associated with intensely labeled neurons) or finely punctate (generally present in moderately or weakly labeled cells). A third pattern, a homogenous deposit associated with the plasma membrane, was found in several regions (Fig. 2A–C). Notably, intensity of the CRF1 immunoreaction product was maximal in neocortical pyramidal cells, Purkinje cells, and most positive neurons in the thalamus, hypothalamus, and brainstem nuclei.
The distribution of CRF1-LI neurons in the four mouse brains studied in detail was essentially identical, with relatively modest variation in labeling intensity among animals. The following is a description of the distribution of CRF1-LI neurons by region.
Telencephalon
Table 1 outlines the distribution of CRF1-LI in the telencephalon.
TABLE 1.
Region | Density1 | Intensity2 |
---|---|---|
Olfactory bulb | ||
Glomerular layer | ++ | ++/ +++3 |
External plexiform layer | + | + |
Mitral cell layer | ++++ | ++ |
Internal plexiform layer | ++ | ++ |
Granular cell layer | ++++ | +/++ |
Accessory olfactory bulb | ||
Mitral cell layer | ++++ | ++ |
Granular cell layer | ++++ | +/++ |
Olfactory tubercle | ||
Polymorphic layer | +++ | +/++ |
Pyramidal layer | ++++ | +/++ |
Island of Calleja | +++ | +/++ |
Taenia tecta | ++++ | ++ |
Claustrum | ++++ | +/++ |
Endopiriform nucleus | +++ | ++ |
Neocortex | ||
Layer I | + | + |
Layer II | ++++ | ++ |
Layer III | ++++ | ++ |
Layer IV | ++++ | + |
Layer V | ++++ | ++++ |
Layer VI | ++++ | +/++ |
Piriform cortex | ||
Layer I | + | ++ |
Layer II | ++++ | ++/+++ |
Layer III | ++++ | ++/+++ |
Entorhinal cortex | ||
Layer IIa | ++++ | ++/+++ |
Layer IIb | +++ | ++ |
Layer III | ++++ | ++ |
Layers V–VI | +++ | ++/+++ |
Perirhinal cortex | ++++ | ++ |
Hippocampal formation | ||
Hippocampus | ||
CA1 pyramidal layer | ++++ | ++ |
CA3a pyramidal layer | ++++ | +++ |
CA3b,c pyramidal layer | ++++ | +/++ |
Dentate gyrus | ||
Hilus | ++ | +++ |
Granular layer | ++++ | + |
Molecular layer | −/+ | ++ |
Subiculum | +++ | +++/ ++++ |
Amygdala | ||
Medial nucleus | ++++ | ++ |
Cortical nucleus | ++++ | +/++ |
Central nucleus | ||
Medial | +++ | +/++ |
Lateral | ++++ | +/++ |
Basal nucleus | +++ | ++++ |
Lateral nucleus | +++ | + |
Bed nucleus of stria | ||
terminalis | ||
Medical part | +++ | ++ |
Lateral part | ++++ | ++ |
Basal ganglia | ||
Caudate-putamen | ++++ | + |
Nucleus accumbens | ++++ | +/++ |
Fundus striati | +++ | ++ |
Globus pallidus | ++ | ++/+++ |
Ventral pallidus | ++ | +++ |
Entopeduncular nucleus | ++ | +++ |
Septum | ||
Lateral septal nucleus | ++++ | +++ |
Medical septal nucleus | ++++ | ++/+++ |
Diagonal band of Broca | ||
Vertical limb | +++ | +++ |
Horizontal limb | +++ | +++ |
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low, 10–25%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
Staining intensity: +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
Two scores are noted because the region contains cell populations with different labeling intensity.
Olfactory bulb and tubercle
In the olfactory bulb (Fig. 3A), many periglomerular cells were intensely CRF1-LI labeled and thus outlined the glomeruli that were unstained. In addition, a few large, multipolar, intensely labeled neurons were observed just beneath the glomerular layer. Mitral cells were moderately or weakly immunoreactive, and some weakly labeled neurons were also present in the external and internal plexiform layers. In addition, some immunoreactive puncta were observed in the internal plexiform layer and, rarely, in the external plexiform layer. The granular layer contained numerous labeled puncta and scattered CRF1-LI neurons. The distribution pattern of CRF1-LI in the accessory olfactory bulb resembled that found in the main bulb; conversely, most neurons in the anterior olfactory nucleus were CRF1-ir. Within the olfactory tubercle (Fig. 3B), moderately CRF1-LI-labeled neurons were prominent in the pyramidal layer. Scattered large, multipolar, intensely labeled neurons and some medium-size, weakly labeled cells were seen in the polymorphic layer, but none in the plexiform layer. The islands of Calleja contained moderately labeled CRF1 granular reaction products, whereas neurons in the taenia tecta were moderately immunoreactive.
Cerebral cortex
Neocortical areas contained a large number of CRF1-LI neurons, the intensity of which differed substantially across regions. The most intensely labeled neurons occurred in the cingulate cortex and in the somatosensory area of the frontoparietal cortex, followed by the motor area of frontoparietal cortex. CRF1-LI neurons in the association areas of the striate and temporal cortices were characterized by moderately intense reaction product. The laminar distribution of CRF1-LI-labeled neurons was striking: in the cingulate, frontoparietal, and most other neocortical regions, whereas immunopositive neurons were distributed throughout layers II–VI, maximal intensity of the reaction product was found in layer V, most notably in the frontoparietal cortex motor area (Fig. 3C). In addition, rare CRF1-LI neurons were observed in layer I and in subcortical white matter. Within piriform cortex, moderately labeled CRF1-ir neurons were common in both the pyramidal (II) and polymorphic (III) layers, intermingled with a smaller population of intensely labeled cells (Fig. 3D). In the entorhinal cortex, many moderately labeled neurons were distributed in layers II and III, accompanied by a scattered population of large, multipolar, intensely labeled neurons. CRF1-LI neurons in layers V–VI were moderately labeled (Fig. 3E). Perirhinal cortex contained CRF1-LI-labeled neurons uniformly throughout layers II and III.
Hippocampal formation
Within the hippocampus, CRF1-LI-containing neurons were most prominent in the pyramidal cell layer: the CA1 pyramidal cell layer was rich in moderately labeled puncta and contained several intensely labeled large neurons. CA2 was distinguished by intense or moderate labeling of virtually all pyramidal neurons. In CA3, maximal intensity of CRF1-ir was found in CA3a, with a gradual decline over CA3b and a fainter signal over CA3c. Outside the pyramidal layer, only occasional medium-sized, multipolar or fusiform CRF1-ir neurons were scattered in the strata oriens, lacunosum-moleculare, and radiatum (Fig. 4A,B). Within the dentate gyrus, granule cell somata were outlined by a fine mesh of weakly stained puncta, and occasional strongly labeled basket-like neurons were visible. Large, polymorphic, intensely labeled neurons were present in the hilus, whereas little CRF1-LI was observed in the molecular layer (Fig. 4A,C). Within the subiculum, many pyramidal neurons were intensely labeled (Fig. 4D).
Amygdala
Large, intensely labeled neurons were widely distributed throughout the basal nucleus (Fig. 5A,B). The staining pattern of the accessory basal nucleus consisted of weakly labeled medium-sized neurons, and this pattern was shared by the medial nucleus: in both nuclei, only a portion of the cell surface typically showed CRF1-LI (Fig. 5C). Most neurons were immunoreactive in the anterior cortical nucleus, with a similar pattern but lower intensity than in the medial nucleus. In the central nucleus (ACe), weak to moderate CRF1-LI labeling was found in both lateral and medial divisions, but with a different staining pattern: whereas immunoreactivity in the lateral division consisted of punctate deposits, the medial division pattern consisted of crescent-shaped contours (similar to the pattern found in medial and accessory basal nuclei; Fig. 5D). Finally, weakly labeled neurons were present in the lateral nucleus. Within the bed nucleus of stria terminalis (considered a part of the “extended amygdala”), moderately labeled puncta were abundant in both medial and lateral areas (not shown).
Basal forebrain
Most lateral septal nucleus neurons showed intense CRF1-LI. Interestingly, each subnucleus demonstrated a distinct immunoreactivity pattern (Fig. 6A–C): the dorsal region contained many medium-size neurons with granular CRF1-LI deposits (Fig. 6B), whereas the intermediate region also contained (medially) cells with a fine punctate CRF1-LI pattern and short processes. A third pattern, consisting of large granular deposits without a distinct neuronal contour, was observed in the ventral region of this septal nucleus (Fig. 6C). The medial septum contained many large, intensely or moderately labeled neurons, whereas multipolar, intense CRF1-LI-labeled magocellular neurons were abundant in both the horizontal and vertical limbs of the diagonal band of Broca (Fig. 6D).
Basal ganglia
Most CRF1-LI neurons in the striatum (caudate-putamen) were weakly labeled and were accompanied by scattered medium-sized, intensely labeled cells (Fig. 6E). A similar but more intense labeling pattern was evident in the nucleus accumbens (Fig. 6F). The fundus striati and ventral endopiriform nucleus were characterized by abundant, moderately CRF1-LI neurons. A population of larger, multipolar or fusiform process-possessing neurons was encountered in the globus pallidus and the ventral pallidum (Fig. 6F), whereas the entopeduncular nucleus contained moderate numbers of intensely CRF1-LI cells.
Diencephalon
Table 2 outlines the distribution of CRF1-LI neurons in the diencephalon.
TABLE 2.
Region | Density1 | Intensity2 |
---|---|---|
Habenula | ||
Medial part | ++++ | +++ |
Lateral part | ++ | ++ |
Thalamus | ||
Anterodorsal nucleus | ++ | +++/++++3 |
Antroventral nucleus | +++ | ++ |
Anteromedial nucleus | +++ | +++ |
Mediodorsal nucleus | +++ | +++ |
Lateral dorsal nucleus | ++ | +++ |
Lateral postrior nucleus | ++ | +++ |
Ventral lateral nucleus | ++ | +++ |
Ventral postrolateral nucleus | ++ | +++ |
Ventral postromedial nucleus | ++ | +++ |
Paraventricular nucleus | +++ | +++/++++ |
Midline nuclear group | ++ | ++/+++ |
Intralaminar nuclear group | ++ | ++/+++ |
Thalamic reticular nucleus | ++ | +/++ |
Hypothalamus | ||
Medial preoptic area | +++ | +++ |
Lateral preoptic area | +++ | ++ |
Suprachiasmatic nucleus | +++ | ++ |
Retrochiasmatic nucleus | ++ | + |
Supraoptic nucleus | ++++ | ++++ |
Paraventricular nucleus | ||
Medial parvocellular division | +++ | +++/++++ |
Magnocellular division | + | + |
Ventromedial nucleus | ++++ | ++/+++ |
Arcuate nucleus | ++++ | +++/++++ |
Anterior hypothalamic area | +++ | ++ |
Lateral hypothalamic area | +++ | +/++ |
Dorsal hypothalamic area | +++ | + |
Dorsomedial nucleus | +++ | + |
Median eminence | + | +++ |
Subthalamic nucleus | ++++ | ++/+++ |
Zona incerta | +++ | +/++ |
Medial geniculate body | +++ | +++ |
Lateral geniculate body | +++ | ++/+++ |
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low, 10–25%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
Staining intensity; +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
Two scores are noted because the region contains cell populations with different labeling intensity.
Habenula
Small neurons in medial habenula were intensely CRF1-LI labeled, whereas lateral habenula showed numerous moderately CRF1-LI neurons and scattered intensely labeled cells (Fig. 7A).
Thalamus
The anterior nuclear group demonstrated numerous CRF1-LI strongly labeled neurons (in the anterodorsal and anteromedial nuclei) and moderately labeled ones (anteroventral nucleus) (Fig. 7A). Many neurons with intensely labeled somata and short processes were found in the mediodorsal nucleus. In the lateral nuclear group, the dorsal and posterior nuclei contained multipolar or triangular intensely CRF1-LI neurons possessing short processes. In the ventral group, intensely labeled neurons were abundant in the lateral, posterolateral, and posteromedial nuclei, as well as in the midline nuclear group (paratenial, paraventricular, and reuniens nuclei) and in the intralaminar nuclear group. In the thalamic reticular nucleus, only weak or moderate CRF1-LI was found (Fig. 7B).
Hypothalamus
Within hypothalamus, most CRF1-LI labeling of neurons was intense, especially in the supraoptic, paraventricular (PVN), ventromedial (VMH), and arcuate nuclei (Fig. 8A–F). The medial preoptic area contained numerous highly CRF1-LI neurons, reminiscent of those of the amygdaloid medial nucleus, whereas the lateral preoptic nucleus contained triangular or fusiform, moderately labeled cells bearing several short processes. The suprachiasmatic nucleus was characterized by densely immunoreactive neuropil, whereas the retrochias-matic area contained a few weakly CRF1-LI-positive neurons in conjunction with scattered intensely CRF1-LI-positive puncta. Neurons in the supraoptic nucleus were more strongly immunolabeled than those in the suprachiasmatic nucleus (Fig. 8D). Parvocellular neurons of the PVN demonstrated exceptionally strong CRF1-LI; in contrast, few positive neurons were present in the magnocellular divisions (Fig. 8A–C). In the VMH, neurons were intensely labeled ventrolaterally and moderately labeled in the dorsomedial part, in a granular pattern. Intensity of CRF1-ir in the arcuate nucleus was higher than that observed in the VMH (Fig. 8E,F). Staining intensity of CRF1-LI in neurons of the posterior lateral hypothalamic area was mostly weak or moderate. Interestingly, several subependymal neurons in the median eminence showed CRF1-LI (Fig. 8E).
Subthalamus and geniculate bodies
Subthalamic neurons showed CRF1-LI, as did most zona incerta cells (Fig. 7C). In the lateral geniculate body, neurons were generally intensely labeled dorsally and moderately or weakly labeled in the ventral parts, whereas both parts of the medial geniculate body contained intensely immuno-reactive neurons.
Mesencephalon
Table 3 outlines the distribution of CRF1-LI-expressing neurons in the mesencephalon. A large number of CRF1-LI-labeled neurons was observed in the tectum. Within layers II–VII of the superior colliculus, these neurons were moderately or weakly immunoreactive, accompanied by a few large, multipolar, deeply labeled cells in the lateral part of layer VI and occasionally in layer VII (Fig. 9A). The most striking feature of the inferior colliculus was large, multipolar or triangular, strongly CRF1-LI neurons in both the cortical and central nuclei, where most medium-sized neurons were moderately stained (Fig. 9B). Comparison of the dorsal and lateral inferior colliculus cortex revealed a few CRF1-LI neurons in the latter.
TABLE 3.
Region | Density1 | Intensity2 |
---|---|---|
Superior colliculus | ++ | +/++3 |
Inferior colliculus | ++ | +/++ |
Tegmental nuclei | +++ | ++/+++ |
Pedunculopontine nucleus | +++ | +++ |
Red nucleus | ++++4 | +++ |
Substantia nigra | ||
Pars compacta | ++ | +++ |
Pars reticulata | ++ | ++/+++ |
Raphe nuclei | ||
Dorsal nucleus | ++ | +++/++++ |
Median nucleus | + | ++ |
Edinger-Westphal nucleus | +++ | +/++ |
Principal oculomotor nucleus |
+++ | +++ |
Darkschewitsch nucleus | ||
Nuclei of the trigeminal nerve |
||
Mesencephalic nucleus | ++++ | +++ |
Motor nucleus | ++++4 | +++ |
Principal sensory nucleus |
+++ | +/++ |
Spinal nucleus | ++ | +/++ |
Facial nucleus | ++++4 | +++ |
Vestibular nuclei | +++ | ++/+++ |
Cochlear nuclei | ||
Dorsal nucleus | ++ | ++ |
Ventral nucleus | ++ | +++ |
Vagus nucleus | ++++ | ++++ |
Hypoglossal nucleus | ++++ | +++ |
Solitary nucleus | +++ | +/++ |
Ambiguus nucleus | +++ | ++++ |
Locus coeruleus | +++ | ++++ |
Superior olive | +++ | +++ |
Inferior olive | +++ | ++/+++ |
Nuclei of lateral lemniscus |
+++ | +++ |
Nucleus of trapezoid body | ||
Medial nucleus | ++++ | ++++ |
Lateral nucleus | +++ | ++ |
Cerebellum | ||
Molecular layer | +++ | + |
Purkinje cell layer | ++++ | ++++ |
Granular cell layer | +++ | + |
Cerebellar nuclei | +++ | +++ |
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low, 10–5%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
Staining intensity: +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
Two scores are noted because the region contains cell populations with different labeling intensity.
All large, multipolar neurons were CRF1 immunoreactive.
Within tegmental nuclei, labeling intensity was maximal in the ventral (Fig. 9C), moderate in the laterodorsal, and weak in the dorsal nucleus (Fig. 9C,G). Neurons in the pedunculo-pontine-tegmental and reticulotegmental nuclei were strongly labeled. In red nucleus, most large neurons with short processes were intensely labeled (Fig. 9D). The substantia nigra pars reticulata was characterized by large, multipolar, neurons with intense CRF1-LI, whereas the pars compacta contained medium, moderately to intensely labeled cells (Fig. 9E). Similarly, process-bearing neurons in the interpeduncular nucleus were moderately or intensely labeled. The dorsal raphe nucleus was rich in highly labeled neurons, whereas only modest numbers of intensely stained neurons were observed in the median raphe (Fig. 9G).
Both the accessory (Edinger-Westphal) and principal oculomotor nuclei contained moderate or intense CRF1-LI (Fig. 9F). Neurons with short processes in the Darkschewitsch nucleus were moderately labeled. The mesencephalic nucleus of the trigeminal nerve showed intense CRF-LI in a granular pattern (see Fig. 11A). In addition, many medium-sized, moderately labeled neurons were present in the central gray, particularly dorsally.
Pons and medulla
Pontine and medullary raphe nuclei shared the staining pattern of their mesencephalic counterparts. Within the reticular formation, large, multipolar, intense CRF1-LI neurons were abundant in the pontine and gigantocellular reticular nuclei, whereas only scattered positive neurons resided in the intermediate and lateral nuclei. The locus coeruleus was rich in multipolar, intensely CRF1-LI-labeled neurons (see Fig. 11A). Dorsal parabrachial nuclei were more intensely stained than ventral ones (see Fig. 11B). Large, multipolar neurons in superior olive and nuclei of lateral lemniscus were also intensely stained.
Within trigeminal nerve nuclei, large, multipolar neurons in the motor, principal sensory, and spinal subnuclei showed intense CRF1-LI. In addition, numerous moderately labeled small and medium cells were found in both principal sensory and spinal nuclei (Fig. 10A). The facial nucleus was rich in large, multipolar CRF1-LI neurons (Fig. 10B), whereas the vestibular nuclei (medial, lateral, and superior) contained numerous moderately or in-tensely labeled cells (Fig. 10C). In the cochlear complex, the ventral nucleus had more intense CRF1-LI than the dorsal nucleus, the latter containing rare highly labeled neurons and some moderately immunoreactive neurons (Fig. 11C). Some neurons in vagal, ambiguous, and hypoglossal nuclei showed strong CRF1-LI (Fig. 10D,E). Weak-to-moderate CRF1-LI labeling occurred in medial and lateral divisions of the solitary tract nucleus (Fig. 10F).
Medium-sized, highly labeled CRF1-LI neurons were observed in the medial nucleus of the trapezoid body, in contrast to the occasional, intensely labeled cells of the lateral nucleus (Fig. 11D,E). In the inferior olive, medium-sized CRF1-LI-stained neurons were found (Fig. 11F).
Cerebellum
Purkinje cells showed intense CRF1-LI, in a granular pattern (Figs. 2A, 11G), whereas the granular layer contained only scattered intensely labeled neurons accompanied by abundant weakly labeled puncta. Large, multipolar neurons in the deep cerebellar nuclei were intensely stained, whereas the cerebellar white matter was devoid of CRF1-LI.
DISCUSSION
The current immunocytochemical study describes the distribution of CRF1-LI throughout the mouse brain. The results indicate that 1) CRF1-LI is generally localized to the cell membrane and is further characterized as granular, punctate, or homogenous deposits; 2) CRF1-LI-labeled neurons are morphologically heterogeneous both within and among brain structures; 3) CRF1-LI is widely and selectively distributed in discrete regions of the mouse brain, in a pattern that—with notable exceptions—generally conforms to that of CRF1 mRNA; and 4) a gradient of CRF1-LI labeling intensity exists, with the highest found in certain hypothalamic nuclei, neocortex, septum, basal amygdala, thalamus, select brain stem regions, and cerebellar Purkinje cells.
CRF1 immunoreaction product was generally localized to the cell membrane. This result is consistent with evidence indicating that this receptor is a G-protein-coupled, membrane-bound protein (Chang et al., 1993; Perrin et al., 1993; Castro et al., 1996). Of the several patterns of CRF1-LI observed in this study (Fig. 2A–C), some may signify receptor clustering (granular and punctate deposits). In addition, the spectrum of cellular distribution patterns of CRF1-LI was remarkable, both within a given nucleus as well as among regions. Most commonly, punctate or granular CRF1-LI outlined a neuronal profile consisting of the soma with or without dendritic processes. In some cases, CRF1-LI outlined only part of the cell surface, suggesting somatic innervation, perhaps by a spatially discrete bundle of axons (e.g., the climbing fiber innervation of cerebellar molecular layer neurons). Interestingly, numerous CRF1-LI-labeled puncta were observed in certain regions such as the granular layers of the olfactory bulb and cerebellum, suggesting a presynaptic location of CRF1. Thus, the findings of this study are consistent with a potential for not only the post- but also presynaptic location of CRF1. However, electron microscopic (EM) studies are required to demonstrate the presence of presynaptic CRF1 definitely.
In general, neurons with CRF1-LI were observed in target regions of CRH-expressing local circuit and projection neurons. An eloquent example of this notion was evident in the amygdala. In the ACe, CRH-containing terminals are abundant and have been shown to arise from cell bodies located in the lateral hypothalamus and dorsal raphe, as well as from intrinsic CRH neurons in the ACe (Swanson et al., 1983; Uryu et al., 1992). In the present study, we observed that essentially all ACe neurons were CRF1-LI positive. This indicates that in the ACe, CRF1-ir neurons may be innervated by CRH-expressing cells originating both within and outside the amygdala. Interestingly, the density and intensity of CRF1-immunoreaction product in the ACe were high. In contrast, CRF1 mRNA expression in the ACe has been found to be modest (Potter et al., 1994; Chalmers et al., 1995; Avishai-Eliner et al., 1996). Thus, it may be suggested that the CRF1-LI in the ACe may originate in the somata of other nuclei (e.g., lateral amygdala; Pitkänen et al., 1997) and transported to ACe. An additional, intriguing possibility is that the ACe may contain novel, as yet uncharacterized, ligand for this receptor (e.g., Weninger et al., 1999). Whereas levels of CRF1-LI and mRNA are somewhat discordant in the ACe, the results of the current study—showing intense labeling of magnocellular neurons in basal nucleus—are in accordance with levels of CRF1 mRNA expression and CRH receptor binding in this nucleus (De Souza, 1987; Potter et al., 1994; Chalmers et al., 1995; Avishai-Eliner et al., 1996).
CRF1-LI was localized to regions receiving CRH-containing projections from the amygdala. Indeed, the amygdala is considered an origin of major CRH-containing pathways, emanating from the ACe, the major output nucleus for amygdaloid projections to the brainstem and hypothalamus (Swanson et al., 1983; Sakanaka et al., 1986; Gray and Bingaman, 1996; Pitkänen et al., 1997). CRH neurons in ACe have been shown to project to the bed nucleus of the stria terminalis (BNST), lateral hypothalamus, midbrain central gray, parabrachial nucleus, mesencephalic nucleus of the trigeminal nerve, mesencephalic reticular formation, solitary tract nucleus, and vagal nucleus (Veening et al., 1984; Sakanaka et al., 1986; Moga et al., 1989). In view of the widespread CRH projections from the ACe, it is not surprising that abundant CRF1-LI-expressing neurons are observed in the current study. Indeed, the distribution of CRF1-LI-labeled neurons demonstrated in this study highly overlaps that of target regions of CRH-expressing projections from the ACe. An additional CRH-expressing group of projection neurons originates in the amygdaloid corticomedial nucleus, innervating the VMH (Sakanaka et al., 1986). Accordingly, the current study demonstrated numerous CRF1-LI-labeled neurons in VMH.
CRF1-LI-positive neurons were abundant in most cholinergic nuclei of the basal forebrain, including the septum and the diagonal band of Broca. Interestingly, we found high levels of CRF1-LI in both the lateral and medial septum, whereas reports on the distribution of CRF1 mRNA have suggested a preferential localization to the medial septum (Chalmers et al., 1995). In addition, within the lateral septum, regional differences were evident in the cellular pattern of CRF1-ir, implying regional specificity in the localization and perhaps physiological functions of this receptor. Thus, the demonstration of CRF1-LI-positive neurons in cholinergic nuclei afferent to the hippocampal formation may suggest that the receptor participates in modulation of cholinergic input to the hippocampus.
The current study demonstrated a rich array of CRF1-LI-expressing neurons in the hippocampal formation. CRH has been shown to influence directly synaptic function in hippocampal CA1 (Aldenhoff et al., 1983; Smith and Dudek, 1994) and CA3 (Hollrigel et al., 1998) and to excite hippocampal neurons both in vivo (Baram et al., 1997) and in vitro (Aldenhoff et al., 1983; Smith and Dudek, 1994; Hollrigel et al., 1998). These effects may be important in modulating learning and memory processes (Liang and Lee, 1988; Lee et al., 1993; Behan et al., 1995). Furthermore, recent evidence indicates that at least some of these direct effects of CRH on hippocampal neurons are mediated by CRF1 (Baram et al., 1997).
In the absence of CRH-containing afferent projections to the hippocampus, the endogenous ligand for CRF1—shown here to reside primarily on pyramidal layer neurons—is likely to be CRH found in local hippocampal interneurons, as described by Swanson et al. (1983) and Sakanaka et al. (1987). Recently most of these neurons have been found to be basket and chandelier cells, synapsing on soma and axon initial segment of pyramidal neurons, respectively (Yan et al., 1998b). Thus, local CRH-expressing interneurons are the likely source of ligand activating the abundant CRF1-LI on hippocampal pyramidal layer neurons. This study documented a particularly striking density and intensity of CRF1 immunoreactivity in CA3 pyramidal neurons. In this context, it is interesting to note that the excitatory and particularly the excitotoxic effects of CRH are maximal on CA3 hippocampal neurons (Baram and Ribak, 1995; Ribak and Baram, 1996).
In the hypothalamus, the current study demonstrated an abundant population of generally intense CRF1-LI labeling of neurons in the PVN, VMH, and supraoptic and arcuate nuclei. While a small proportion (about 24%; 96 of 398) of PVN magnocellular neurons showed faint CRF1-LI, parvocellular neurons were very intensely labeled. Of these, most were concentrated in the anterior, medial, and lateral parts of the parvocellular division (Swanson and Kuypers, 1980; Swanson et al., 1983). Previous studies have demonstrated that CRH-expressing parvocellular neurons of the dorsomedial division of PVN give rise to the pathway terminating in the external zone of the median eminence (Swanson et al., 1987; reviewed in Sawchenko and Swanson, 1990) that controls the release of ACTH from the pituitary. These CRH neurons thus participate in the control of ACTH release from the anterior pituitary, a key neuroendocrine component of the response to stress. In addition to this stress axis-related role, subpopulations of PVN CRH neurons, such as those residing in the medial and lateral parvocellular regions, project to autonomic cell groups in the brainstem and spinal cord (Sawchenko, 1987). The current study documents the presence of CRF1-LI in PVN regions containing both neuroendocrine and autonomic-projecting cells. These receptors may thus be positioned to modulate both the neuroendocrine and autonomic functions of CRH.
The current study demonstrates a striking abundance of CRF1-LI in the PVN. This may be contrasted with previous in situ hybridization studies, showing unexpectedly little CRF1 mRNA expression in the PVN of unstressed rats (Potter et al., 1994; Chalmers et al., 1995; Avishai-Eliner et al., 1996). However, CRF1 mRNA levels were highly increased by stressful manipulations (Luo et al., 1994; Rivest et al., 1995; Imaki et al., 1996; Hatalski et al., 1998), as well as by intracere-broventricular administration of CRH. The current study demonstrated CRF1-LI in parvocellular neurons from hypothalami of animals obtained under relatively stress-free circumstances (see Materials and Methods). This indicates that high CRF1 protein levels may exist concurrent with modest steady-state CRF1 mRNA levels. This is consistent both with a long half-life of CRF1 and with regulation of receptor levels at the protein level. Because receptor binding studies have generally demonstrated modest levels of CRH binding in the PVN (De Souza and Kuhar, 1986), our data may suggest increased sensitivity of the immunocytochemical approach. In agreement with our results, Radulovic et al. (1998) recently reported the presence of CRF1-ir neurons in PVN of both rat and mouse.
It should be noted that it is unlikely that the CRF1-LI observed in this study was a result of cross-reactivity with CRF2. Substantial homology exists between CRF1 and CRF2 proteins, and the immunogenic epitope used to generate the antiserum used here shares 17 of 20 amino acids with the C-terminus of CRF2. However, Western blotting at high antiserum concentration of mouse brain of several strains revealed a single band. In addition, the overall distribution of CRF1-ir in the current study matched that reported for CRF1 binding and mRNA, and not that of CRF2. Finally, using the antiserum on mouse heart, known to express CRF2 but not CRF1, no immunoreactivity was evident, again strongly suggesting that the antiserum does not recognize CRF2.
In the present study, neurons strongly labeled for CRF1-LI were also evident in the supraoptic nucleus. In view of the association of such neurons with CRH-expressing cells in PVN (vide supra), it is notable that a subset of supraoptic nucleus neurons have been shown to synthesize CRH (Kawata, 1983). CRF1-LI was abundant in both the dorsomedial and ventromedial VMH. At the mRNA level, CRF1 expression in the VMH has been found to be low compared with that of CRF2 in both adult and immature animals (Chalmers et al., 1995; Eghbal-Ahmadi et al., 1998). The VMH functions to regulate food intake and energy balance. In addition, it is involved with integrating inputs from the HPA-axis, circadian rhythm, and sensory relay centers (Lovenberg et al., 1995; Eghbal-Ahmadi et al., 1999). However, the relative roles of CRF1 and CRF2 in mediating the effects of CRH and similar ligands in the VMH are not fully understood. The relatively high levels of VMH CRF1-LI found in this study suggest that this receptor may participate in mediating some of the effects of CRH (and related ligands) in this region.
CRF1-LI was abundant in monoaminergic cell groups such as the locus coeruleus, raphe, ventral tegmentum, and substantia nigra. Of these, the locus coeruleus has been shown to contain CRH-expressing neurons and fibers. A number of studies have suggested that CRH may function as a neurotransmitter in this region, involved with central integration of autonomic, behavioral, and anxiogenic effects of stressful stimuli (Valentino et al., 1992; Lehnert et al., 1998). For example, CRH injected into the rodent locus coeruleus produces an anxiogenic response (Owens and Nemeroff, 1993). In this regard, the present study provides an anatomical basis for the involvement of the locus ceruleus CRF1 in mediating anxiety-related effects of CRH.
CRF1-LI was abundant in cerebellar circuits. CRH has been localized to cerebellar mossy fiber projections originating in vestibular-related brainstem nuclei (Cha and Foote, 1988; Cummings et al., 1994) and to the climbing fibers and their origin, the inferior olive (Young et al., 1986; Cummings et al., 1994; Chang et al., 1996). In accordance with the functional role of CRH as a cerebellar neurotransmitter, previous studies have demonstrated the expression of CRF1 and CRF2 mRNAs in the molecular and granular layers, sites of termination of climbing and mossy fibers, respectively (Potter et al., 1994; Chalmers et al., 1995). In the present study, almost all Purkinje cells showed intense CRF1-LI, whereas these levels were generally low in both molecular and granular layers. Thus, whereas the current immunocytochemical data correlate with mRNA distribution in Purkinje cells (Chalmers et al., 1995; King et al., 1997), the current study shows low CRF1-LI levels in the granular layer, considered rich in CRF1 mRNA. This apparent discrepancy may be due to the synthesis of CRF1 within cell bodies located in the granular layer and transport of the protein away from the soma, located in the granular layer, resulting in low signal intensity in this layer (Table 3).
The current study focused on CRF1 detection in the mouse brain; the distribution may differ from that in rat. Thus, Radulovic et al. (1998) reported significant, although mainly quantitative, species differences in the distribution of the receptor between the rat and mouse. Compared with the rat, the mouse was found to express less CRF1 protein in the neocortex and basal amygdala and significantly larger amounts of CRF1 protein in several subcortical regions including the substantia nigra, central gray, red and Darkschewitsch nuclei, and pontine reticular nuclei.
In summary, the present immunocytochemical study reveals that the CRF1-LI is widely yet selectively expressed in the mouse brain and that its localization generally overlaps target regions of CRH projections. In addition, CRF1-LI distribution is generally congruent with previously published data on CRF1 mRNA expression. However, discrepancies do exist in several regions including the central amygdaloid nucleus, septum, locus coeruleus, certain hypothalamic nuclei, and the cerebellar granular layer. These, as discussed above, may be due to differential regulation of receptor transcription and protein, to protein transport, to the cellular detail afforded by the current study, or to the presence of as yet undiscovered or cross-reacting ligands and receptors, respectively.
ACKNOWLEDGMENTS
Grant sponsor: National Institutes of Health; Grant number: NS 28912; Grant sponsor: University of California Systemwide Biotechnology Research and Education Program; Grant number: 98-02.
We thank Drs. O. Steward, A. Pitkänen, L. Seress, H. Yin, and R. Bender for their valuable comments on the manuscript.
Abbreviations
- 3
principal oculomotor nucleus
- 3V
third ventricle
- 7
facial nucleus
- 10
dorsal motor nucleus of vagus
- 12
hypoglossal nucleus
- AB
accessory basal amygdaloid nucleus
- aca
anterior commisure, anterior part
- Acb
accumbens nucleus
- ACe
central amygdaloid nucleus
- AD
anterodorsal thalamic nucleus
- AHy
anterior hypothalamic area
- Amb
ambiguous nucleus
- ap
anterior parvocellular part, paraventricular hypothalamic nucleus
- Arc
arcuate hypothalamic nucleus
- AV
anteroventral thalamic nucleus
- Bmc
basal amygdaloid nucleus, magnocellular division
- CA1–3
cornu ammonis, hippocampus
- cc
corpus callosum
- CC
central canal
- CEl
central amygdaloid nucleus, lateral division
- CEm
central amygdaloid nucleus, medial division
- CL
centrolateral thalamic nucleus
- COa
anterior cortical amygdaloid nucleus
- d
dorsal nucleus, inferior olive
- DCo
dorsal cochlear nucleus
- Dk
Darkschewitsch nucleus
- DPB
dorsal parabrachial nucleus
- DR
dorsal raphe nucleus
- DTg
dorsal tegmental nucleus
- ec
external capsule
- En
endopiriform nucleus
- EPl
external plexiform layer of olfactory bulb
- EW
accessory oculomotor nucleus
- FStr
fundus striate
- Gl
glomeruli
- Grc
granular layer of cerebellum
- GrCo
granular layer of cochlear nucleus
- GrDG
granular layer of dentate gyrus
- Hi
hilus of dentate gyrus
- ICj
islands of Calleja
- icp
inferior cerebellar peduncle
- Igr
internal granular layer of olfactory bulb
- IO
inferior olive
- IPl
internal plexiform layer of olfactory bulb
- LC
locus coeruleus
- LDTg
laterodorsal tegmental nucleus
- lfp
longitudinal fasiculus of pons
- LH
lateral hypothalamic area
- Ll
lateral amygdaloid nucleus, lateral division
- Lm
lateral amygdaloid nucleus, medial division
- LMol
stratum lacunosum-moleculare of hippocampus
- lp
lateral parvocellular part, paraventricular hypothalamic nucleus
- LRt
lateral reticular nucleus
- LRtS5
lateral reticular nucleus, subtrigeminal part
- LSD
lateral septal nucleus, dorsal part
- LSI
lateral septal nucleus, intermediate part
- LSV
lateral septal nucleus, ventral part
- LTz
lateral nucleus of trapezoid body
- LV
lateral ventricle
- Lve
lateral vestibular nucleus
- Mcd
medial amygdaloid nucleus, dorsal part of central division
- Mcv
medial amygdaloid nucleus, ventral part of central division
- MD
mediodorsal thalamic nucleus
- ME
median eminence
- Me5
mesencephalic trigeminal nucleus
- MHb
medial habenular nucleus
- Mi
mitral cell layer of olfactory bulb
- Mo5
motor trigeminal nucleus
- Mol
molecular layer of cerebellum
- MolDG
molecular layer of dentate gyrus
- mp
medial parvocellular part, paraventricular hypothalamic nucleus
- MS
medial septal nucleus
- MSO
medial superior olive
- MTz
medial nucleus of trapezoid body
- MVe
medial vestibular nucleus
- opt
optic tract
- Or
oriens layer of hippocampus
- PAC
periamygdaloid nucleus
- PCRt
parvocellular reticular nucleus
- PGi
paragigantocellular reticular nucleus
- Pir
piriform cortex
- pm
posterior magnocellular part, paraventricular hypothalamic nucleus
- Pn
pontine nuclei
- PnC
pontine reticular nucleus, caudal
- PnO
pontine reticular nucleus, oral
- Pr5
principal sensory trigeminal nucleus
- Pur
Purkinje cell layer
- PVN
paraventricular hypothalamic nucleus
- py
pyramidal tract
- Py
pyramidal layer of hippocampus
- PyTu
pyramidal layer of olfactory bulb
- Rad
stratum radiatum of hippocampus
- Rt
reticular thalamic nucleus
- scp
superior cerebellar peduncle
- sm
stria medullaris thalamus
- SNC
substantia nigra pars compacta
- SNR
substantia nigra pars reticulate
- SO
supraoptic hypothalamic nucleus
- sol
solitary tract
- SolL
nucleus solitary tract, lateral part
- SolM
nucleus solitary tract, medial part
- STh
subthalamic nucleus
- Su7
suprafacial nucleus
- VCo
ventral cochlear nucleus
- VDBV
nucleus of vertical limb of diagonal band, ventral part
- VL
ventrolateral thalamic nucleus
- VLL
ventral nucleus of lateral lemniscus
- VM
ventromedial thalamic nucleus
- VMH
ventromedial hypothalamic nucleus
- VMHDM
ventromedial hypothalamic nucleus, dorsomedial part
- VMHVL
ventromedial hypothalamic nucleus, ventrolateral part
- VP
ventral pallidum
- VPB
ventral parabrachial nucleus
- VTg
ventral tegmental nucleus
- ZI
zona incerta
LITERATURE CITED
- Aldenhoff JB, Gruol DL, Rivier J, Vale W, Siggins GR. Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science. 1983;221:875–877. doi: 10.1126/science.6603658. [DOI] [PubMed] [Google Scholar]
- Avishai-Eliner S, Yi SJ, Baram TZ. Developmental profile of messenger RNA for the corticotropin-releasing hormone receptor in the rat limbic system. Brain Res Dev Brain Res. 1996;91:159–163. doi: 10.1016/0165-3806(95)00158-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baram TZ, Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. TINS. 1998;21:471–476. doi: 10.1016/s0166-2236(98)01275-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baram TZ, Ribak CE. Peptide-induced infant status epilepticus causes neuronal death and synaptic reorganization. Neuroreport. 1995;6:277–280. doi: 10.1097/00001756-199501000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 1997;770:89–95. doi: 10.1016/s0006-8993(97)00759-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Behan DP, Heinrichs SC, Troncoso JC, Liu XJ, Kawas CH, Ling N, De Souza EB. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer’s disease. Nature. 1995;378:284–287. doi: 10.1038/378284a0. [DOI] [PubMed] [Google Scholar]
- Castro MG, Morrison E, Perone MJ, Brown OA, Murray CA, Ahmed I, Perkins AV, Europe-Finner G, Lowenstein PR, Linton EA. Corticotrophin-releasing hormone receptor type 1: generation and characterization of polyclonal antipeptide antibodies and their localization in pituitary cells and cortical neurones in vitro. J Neuroendocrinol. 1996;8:521–531. doi: 10.1046/j.1365-2826.1996.04866.x. [DOI] [PubMed] [Google Scholar]
- Cha CI, Foote SL. Corticotropin-releasing factor in olivocerebellar climbing-fiber system of monkey (Saimiri sciureus and Macaca fascicularis): parasagittal and regional organization visualized by immunohistochemistry. J Neurosci. 1988;8:4121–4137. doi: 10.1523/JNEUROSCI.08-11-04121.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15:6340–6350. doi: 10.1523/JNEUROSCI.15-10-06340.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chang CP, Pearse RVII, O’Connell S, Rosenfeld MG. Identification of a seven trans-membrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 1993;11:1187–1195. doi: 10.1016/0896-6273(93)90230-o. [DOI] [PubMed] [Google Scholar]
- Chang D, Yi SJ, Baram TZ. Developmental profile of corticotropin releasing hormone messenger RNA in the rat inferior olive. Int J Dev Neurosci. 1996;14:69–76. doi: 10.1016/0736-5748(95)00072-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA. 1993;90:8967–8971. doi: 10.1073/pnas.90.19.8967. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen YC, Chen QS, Lei JL, Wang SL. Physical training modifies the age-related decrease of GAP-43 and synaptophysin in the hippocampal formation in C57BL/6J mouse. Brain Res. 1998a;806:238–245. doi: 10.1016/s0006-8993(98)00770-7. [DOI] [PubMed] [Google Scholar]
- Chen YC, Lei JL, Chen QS, Wang SL. Effect of physical training on the age-related changes of acetylcholinesterase-positive fibers in the hippocampal formation and parietal cortex in the C57BL/6J mouse. Mech Ageing Dev. 1998b;102:81–93. doi: 10.1016/s0047-6374(98)00026-8. [DOI] [PubMed] [Google Scholar]
- Conti LH, Foote SL. Effects of pretreatment with corticotropin-releasing factor on the electrophysiological responsivity of the locus coeruleus to subsequent corticotropin-releasing factor challenge. Neuroscience. 1995;69:209–219. doi: 10.1016/0306-4522(95)00222-5. [DOI] [PubMed] [Google Scholar]
- Cummings SL, Young WS, III, King JS. Early development of cerebellar afferent systems that contain corticotropin-releasing factor. J Comp Neurol. 1994;350:534–549. doi: 10.1002/cne.903500403. [DOI] [PubMed] [Google Scholar]
- De Souza EB. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci. 1987;7:88–100. doi: 10.1523/JNEUROSCI.07-01-00088.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Souza EB, Kuhar MJ. Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: methods and overview. Methods Enzymol. 1986;124:560–590. doi: 10.1016/0076-6879(86)24040-9. [DOI] [PubMed] [Google Scholar]
- De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci. 1985;5:3189–3203. doi: 10.1523/JNEUROSCI.05-12-03189.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dolorfo CL, Amaral DG. Entorhinal cortex of the rat: organization of intrinsic connections. J Comp Neurol. 1998;398:49–82. doi: 10.1002/(sici)1096-9861(19980817)398:1<49::aid-cne4>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
- Eghbal-Ahmadi M, Hatalski CG, Lovenberg TW, Avishai-Eliner S, Chalmers DT, Baram TZ. The developmental profile of the corticotropin releasing factor receptor (CRF2) in rat brain predicts distinct age-specific functions. Brain Res Dev Brain Res. 1998;107:81–90. doi: 10.1016/s0165-3806(98)00002-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eghbal-Ahmadi M, Avishai-Eliner S, Hatalski CG, Baram TZ. Differential regulation of the expression of corticotropin-releasing factor receptor type 2 (CRF2) in hypothalamus and amygdala of the immature rat by sensory input and food intake. J Neurosci. 1999;19:3982–3991. doi: 10.1523/JNEUROSCI.19-10-03982.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ehlers CL, Henriksen SJ, Wang M, Rivier J, Vale W, Bloom FE. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res. 1983;278:332–336. doi: 10.1016/0006-8993(83)90266-4. [DOI] [PubMed] [Google Scholar]
- Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev Neurobiol. 1996;10:155–168. doi: 10.1615/critrevneurobiol.v10.i2.10. [DOI] [PubMed] [Google Scholar]
- Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, De Souza EB. Characterization of corticotropin-releasing factor receptor subtypes. Ann NY Acad Sci. 1996;780:60–80. doi: 10.1111/j.1749-6632.1996.tb15112.x. [DOI] [PubMed] [Google Scholar]
- Hatalski CG, Guirguis C, Baram TZ. Corticotropin releasing factor mRNA expression in the hypothalamic paraventricular nucleus and the central nucleus of the amygdala is modulated by repeated acute stress in the immature rat. J Neuroendocrinol. 1998;10:663–669. doi: 10.1046/j.1365-2826.1998.00246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hollrigel GS, Chen K, Baram TZ, Soltesz I. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience. 1998;84:71–79. doi: 10.1016/s0306-4522(97)00499-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Imaki J, Imaki T, Vale W, Sawchenko PE. Distribution of corticotropin-releasing factor mRNA and immunoreactivity in the central auditory system of the rat. Brain Res. 1991;547:28–36. doi: 10.1016/0006-8993(91)90571-c. [DOI] [PubMed] [Google Scholar]
- Imaki T, Naruse M, Harada S, Chikada N, Imaki J, Onodera H, Demura H, Vale W. Corticotropin-releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus. Brain Res Mol Brain Res. 1996;38:166–170. doi: 10.1016/0169-328x(96)00011-3. [DOI] [PubMed] [Google Scholar]
- Kawata M, Hashimoto K, Takahara J, Sano Y. Immunohistochemical identification of neurons containing corticotropin-releasing factor in the rat hypothalamus. Cell Tissue Res. 1983;230:239–246. doi: 10.1007/BF00213802. [DOI] [PubMed] [Google Scholar]
- King JS, Madtes P, Jr, Bishop GA, Overbeck TL. The distribution of corticotropin-releasing factor (CRF), CRF binding sites and CRF1 receptor mRNA in the mouse cerebellum. Prog Brain Res. 1997;114:55–66. doi: 10.1016/s0079-6123(08)63358-0. [DOI] [PubMed] [Google Scholar]
- Kostich WA, Chen A, Sperle K, Largent BL. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol. 1998;12:1077–1085. doi: 10.1210/mend.12.8.0145. [DOI] [PubMed] [Google Scholar]
- Lee EH, Lee CP, Wang HI, Lin WR. Hippocampal CRF, NE, and NMDA system interactions in memory processing in the rat. Synapse. 1993;14:144–153. doi: 10.1002/syn.890140207. [DOI] [PubMed] [Google Scholar]
- Lehnert H, Schulz C, Dieterich K. Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus. Neurochem Res. 1998;23:1039–1052. doi: 10.1023/a:1020751817723. [DOI] [PubMed] [Google Scholar]
- Liang KC, Lee EH. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology. 1988;96:232–236. doi: 10.1007/BF00177566. [DOI] [PubMed] [Google Scholar]
- Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA. 1995;92:836–840. doi: 10.1073/pnas.92.3.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Luo X, Kiss A, Makara G, Lolait SJ, Aguilera G. Stress-specific regulation of corticotropin releasing hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J Neuroendocrinol. 1994;6:689–696. doi: 10.1111/j.1365-2826.1994.tb00636.x. [DOI] [PubMed] [Google Scholar]
- Moga MM, Saper CB, Gray TS. Bed nucleus of the stria terminalis: cyto-architecture, immunohistochemistry, and projection to the parabrachial nucleus in the rat. J Comp Neurol. 1989;283:315–332. doi: 10.1002/cne.902830302. [DOI] [PubMed] [Google Scholar]
- Muglia L, Jacobson L, Dikkes P, Majzoub JA. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature. 1995;373:427–432. doi: 10.1038/373427a0. [DOI] [PubMed] [Google Scholar]
- Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp. 1993;172:296–308. doi: 10.1002/9780470514368.ch15. [DOI] [PubMed] [Google Scholar]
- Palchaudhuri MR, Wille S, Mevenkamp G, Spiess J, Fuchs E, Dautzenberg FM. Corticotropin-releasing factor receptor type 1 from Tupaia belangeri—cloning, functional expression and tissue distribution. Eur J Biochem. 1998;258:78–84. doi: 10.1046/j.1432-1327.1998.2580078.x. [DOI] [PubMed] [Google Scholar]
- Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1982. [DOI] [PubMed] [Google Scholar]
- Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology. 1993;133:3058–3061. doi: 10.1210/endo.133.6.8243338. [DOI] [PubMed] [Google Scholar]
- Pitkänen A, Savander V, LeDoux JE. Organization of intra-amygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. TINS. 1997;20:517–523. doi: 10.1016/s0166-2236(97)01125-9. [DOI] [PubMed] [Google Scholar]
- Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA. 1994;91:8777–8781. doi: 10.1073/pnas.91.19.8777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powers RE, DeSouza EB, Walker LC, Price DL, Vale WW, Young WS. Corticotropin-releasing factor as a transmitter in the human olivocerebellar pathway. Brain Res. 1987;415:347–352. doi: 10.1016/0006-8993(87)90218-6. [DOI] [PubMed] [Google Scholar]
- Radulovic J, Sydow S, Spiess J. Characterization of native corticotropin-releasing factor receptor type 1 in the rat and mouse central nervous system. J Neurosci Res. 1998;54:507–521. doi: 10.1002/(SICI)1097-4547(19981115)54:4<507::AID-JNR8>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
- Ribak CE, Baram TZ. Selective death of hippocampal CA3 pyramidal cells with mossy fiber afferents after CRH-induced status epilepticus in infant rats. Brain Res Dev Brain Res. 1996;91:245–251. doi: 10.1016/0165-3806(95)00183-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci. 1995;15:2680–2695. doi: 10.1523/JNEUROSCI.15-04-02680.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sakanaka M, Shibasaki T, Lederis K. Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex. Brain Res. 1986;382:213–238. doi: 10.1016/0006-8993(86)91332-6. [DOI] [PubMed] [Google Scholar]
- Sakanaka M, Shibasaki T, Lederis K. Corticotropin releasing factorlike immunoreactivity in the rat brain as revealed by a modified cobalt-glucose oxidase-diaminobenzidine method. J Comp Neurol. 1987;260:256–298. doi: 10.1002/cne.902600209. [DOI] [PubMed] [Google Scholar]
- Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol. 1999;408:365–377. [PubMed] [Google Scholar]
- Sawchenko PE. Evidence for differential regulation of corticotropin-releasing factor and vasopressin immunoreactivities in parvocellular neurosecretory and autonomic-related projections of the paraventricular nucleus. Brain Res. 1987;437:253–263. doi: 10.1016/0006-8993(87)91641-6. [DOI] [PubMed] [Google Scholar]
- Sawchenko PE, Swanson LW. Localization, colocalization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. Fed Proc. 1985;44:221–227. [PubMed] [Google Scholar]
- Sawchenko PE, Swanson LW. Organization of CRF immunoreactive cells and fibers in the rat brain: immunohistochemical studies. In: De Souza EB, Nemeroff CB, editors. Corticotropin-releasing factor: basic and clinical studies of a neuropeptide. Boca Raton, FL: CRC Press; 1990. pp. 29–46. [Google Scholar]
- Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W. The functional neuroanatomy of corticotropin-releasing factor. Ciba Found Symp. 1993;172:5–21. doi: 10.1002/9780470514368.ch2. [DOI] [PubMed] [Google Scholar]
- Sawchenko PE, Brown ER, Chan RK, Ericsson A, Li HY, Roland BL, Kovacs KJ. The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Prog Brain Res. 1996;107:201–222. doi: 10.1016/s0079-6123(08)61866-x. [DOI] [PubMed] [Google Scholar]
- Sidman RL, Angevine JB, Pierce ET. Atlas of the mouse brain and spinal cord. Cambridge, MA: Harvard University Press; 1971. [Google Scholar]
- Siggins GR, Gruol D, Aldenhoff J, Pittman Q. Electrophysiological actions of corticotropin-releasing factor in the central nervous system. Fed Proc. 1985;44:237–242. [PubMed] [Google Scholar]
- Smith BN, Dudek FE. Age-related epileptogenic effects of corticotropin-releasing hormone in the isolated CA1 region of rat hippocampal slices. J Neurophysiol. 1994;72:2328–2333. doi: 10.1152/jn.1994.72.5.2328. [DOI] [PubMed] [Google Scholar]
- Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cyto-architectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol. 1980;194:555–570. doi: 10.1002/cne.901940306. [DOI] [PubMed] [Google Scholar]
- Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983;36:165–186. doi: 10.1159/000123454. [DOI] [PubMed] [Google Scholar]
- Swanson LW, Sawchenko PE, Lind RW. Regulation of multiple peptides in CRF parvo-cellular neurosecretory neurons: implications for the stress response. Prog Brain Res. 1986;68:169–190. doi: 10.1016/s0079-6123(08)60238-1. [DOI] [PubMed] [Google Scholar]
- Swanson LW, Sawchenko PE, Lind RW, Rho JH. The CRH motoneuron: differential peptide regulation in neurons with possible synaptic, paracrine, and endocrine outputs. Ann NY Acad Sci. 1987;512:12–23. doi: 10.1111/j.1749-6632.1987.tb24948.x. [DOI] [PubMed] [Google Scholar]
- Uryu K, Okumura T, Shibasaki T, Sakanaka M. Fine structure and possible origins of nerve fibers with corticotropin-releasing factorlike immunoreactivity in the rat central amygdaloid nucleus. Brain Res. 1992;577:175–179. doi: 10.1016/0006-8993(92)90554-m. [DOI] [PubMed] [Google Scholar]
- Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–1397. doi: 10.1126/science.6267699. [DOI] [PubMed] [Google Scholar]
- Valentino RJ, Wehby RG. Corticotropin-releasing factor: evidence for a neurotransmitter role in the locus ceruleus during hemodynamic stress. Neuroendocrinology. 1988;48:674–677. doi: 10.1159/000125081. [DOI] [PubMed] [Google Scholar]
- Valentino RJ, Page M, Van Bockstaele E, Aston-Jones G. Corticotropin-releasing factor innervation of the locus coeruleus region: distribution of fibers and sources of input. Neuroscience. 1992;48:689–705. doi: 10.1016/0306-4522(92)90412-u. [DOI] [PubMed] [Google Scholar]
- Veening JG, Swanson LW, Sawchenko PE. The organization of projections from the central nucleus of the amygdala to brainstem sites involved in central autonomic regulation: a combined retrograde transport-immunohistochemical study. Brain Res. 1984;303:337–357. doi: 10.1016/0006-8993(84)91220-4. [DOI] [PubMed] [Google Scholar]
- Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, Le Fur G, Caput D, Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett. 1993;335:1–5. doi: 10.1016/0014-5793(93)80427-v. [DOI] [PubMed] [Google Scholar]
- Weninger SC, Muglia LJ, Jacobson L, Majzoub JA. CRH-deficient mice have a normal anorectic response to chronic stress. Regul Pept. 1999;84:69–74. doi: 10.1016/s0167-0115(99)00070-1. [DOI] [PubMed] [Google Scholar]
- Yan XX, Baram TZ, Gerth A, Schultz L, Ribak CE. Co-localization of corticotropin-releasing hormone with glutamate decarboxylase and calcium-binding proteins in infant rat neocortical interneurons. Exp Brain Res. 1998a;123:334–340. doi: 10.1007/s002210050576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yan XX, Toth Z, Schultz L, Ribak CE, Baram TZ. Corticotropin-releasing hormone (CRH)-containing neurons in the immature rat hippocampal formation: light and electron microscopic features and colocalization with glutamate decarboxylase and parvalbumin. Hippocampus. 1998b;8:231–243. doi: 10.1002/(SICI)1098-1063(1998)8:3<231::AID-HIPO6>3.0.CO;2-M. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Young WS, III, Walker LC, Powers RE, De Souza EB, Price DL. Corticotropin-releasing factor mRNA is expressed in the inferior olives of rodents and primates. Brain Res. 1986;387:189–192. doi: 10.1016/0169-328x(86)90010-0. [DOI] [PubMed] [Google Scholar]